📅 On January 2nd, 2024, Alfasigma SpA signed a €170m deal to take over the filgotinib business from Galapagos NV.
💪 This deal will strengthen Alfasigma’s pipeline and expand the use of filgotinib to a third indication.
🌍 It will also enhance Alfasigma’s presence in Northern and Southern European markets.
💼 Additionally, Michele Manto, Galapagos’ former Chief Commercial Officer, will join Alfasigma as Chief Commercial Officer Western Europe.
💪 This deal will strengthen Alfasigma’s pipeline and expand the use of filgotinib to a third indication.
🌍 It will also enhance Alfasigma’s presence in Northern and Southern European markets.
💼 Additionally, Michele Manto, Galapagos’ former Chief Commercial Officer, will join Alfasigma as Chief Commercial Officer Western Europe.
📢 Big Money Deal: Alfasigma Takes Over Filgotinib Business
Introduction:
Alfasigma SpA, based in Bologna, Italy, has signed a €170m deal to acquire the filgotinib business from Galapagos NV. The deal is expected to strengthen Alfasigma’s pipeline and expand the label of filgotinib to a third indication. It will also enhance Alfasigma’s presence in Northern and Southern Europe.
Main points:
- The transaction between Alfasigma SpA and Galapagos NV involves the acquisition of the entire filgotinib business, including marketing authorizations, commercial activities, and development activities for filgotinib in 14 European countries.
- The deal is expected to close in Q1/2024 and will strengthen Alfasigma’s pipeline by adding a new Phase III program to expand the label of filgotinib to a third indication.
- Alfasigma anticipates significant expansion in the Northern European market and a strengthening of its presence in Southern Europe through the acquisition.
- Galapagos will receive a €50m upfront payment, potential milestone payments totaling €120m, and sales-based payments on European sales.
- As part of the deal, Michele Manto, Galapagos’ former Chief Commercial Officer, will join Alfasigma as Chief Commercial Officer Western Europe.
Conclusion:
Alfasigma SpA has signed a €170m deal to acquire the filgotinib business from Galapagos NV. This deal will enhance Alfasigma’s pipeline, expand the label of filgotinib to a third indication, and strengthen its presence in Northern and Southern Europe. It represents a significant step for Alfasigma as it seeks to expand its reach and offerings in the European market.
